Save
REAL-TIME FLUORESCENCE GUIDED-SURGERY WITH ICG FOR SENTINEL LYMPH NODE (SLN) MAPPING IN CASE OF EARLY STAGE CERVICAL OR ENDOMETRIAL CANCER
ESGO eAcademy, Alessandro Buda, 234282
Front-line Ovarian Cancer: Can we do better?: Welcome and introduction
ESGO eAcademy, Sandro Pignata, 202766
Mucinous Ovarian Cancer (MOC): What Is The Reproducibility Of The WHO Classification?
ESGO eAcademy, Mojgan Devouassoux, 202918
Refinement Of High-Risk Endometrial-Cancer (HR-EC) Classification Using DNA Damage Response (DDR) Biomarkers: A Transportec Initiative
ESGO eAcademy, Aurélie AUGUSTE, 202917
PERIOPERATIVE CARE OF THE ELDERLY PATIENT
ESGO eAcademy, Karl Tamussino, 202765
MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE
ESGO eAcademy, Richard Poetter, 202761
Adverse Events After Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Stage III Ovarian Cancer: Phase III OVHIPEC Study
ESGO eAcademy, Simone Koole, 202916
MANAGEMENT OF EARLY STAGES
ESGO eAcademy, David Cibula, 202760
Perioperative Positioning Management In Gynecologic Cancer Surgery: A National NOGGO-AGO Intergroup Survey
ESGO eAcademy, Jenny Katharina Wagner, 202915
WHAT´S NEW IN ANESTHESIA FOR HIGH-RISK PATIENTS: WHAT SURGEONS NEED TO KNOW
ESGO eAcademy, Stephanie Suria, 202763
PATHOLOGY REPORT   
ESGO eAcademy, Maria Rosaria Raspollini, 202759
SHAPING NEW CLINICAL PRACTICE GUIDELINES
ESGO eAcademy, David Cibula, 202758
INITIATING ENHANCED RECOVERY: CHALLENGES AND OPPORTUNITIES
ESGO eAcademy, Lena Wijk, 202762
Hormonal And Fertility Outcome After Fertility Sparing Surgery And Chemotherapy For Ovarian Neoplasms: A Retrospective Study
ESGO eAcademy, Lorenzo Ceppi, 202914
MRI-Based Predictive Factors Of Axillary Lymph Node Metastases In Breast Cancer
ESGO eAcademy, David Atallah, 202913
Experience In Introducing Sentinel Lymph Node Biopsy In Early- Stage Vulva Cancer: A Single Institution Based Prospective Study
ESGO eAcademy, Ligita Paskeviciute Frøding, 202912
ESGO – A STORY OF SUCCESS
ESGO eAcademy, David Cibula, 202757
INTRODUCTION
ESGO eAcademy, Luis Chiva, 202756
SUMMARY AND CONCLUSIONS
ESGO eAcademy, Gabriele Calaminus, 202755
TREATMENT OF RECURRENT AND METASTATIC DISEASE
ESGO eAcademy, Ate van der Zee, 202749
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Cristiana Sessa, 202754
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Dominik Schneider, 202753
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Philippe Morice, 202752
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Gabriele Calaminus, 202751
DIAGNOSIS, STAGING AND PREOPERATIVE WORKUP
ESGO eAcademy, Maaike Oonk, 202747
Practical experiences from CTCA at Southeastern RegionalMedical Center, Georgia USA
ESGO eAcademy, Mansoor Raza Mirza, 202740
Pathological aspects of uterine carcinocarcoma
ESGO eAcademy, Mojgan Devouassoux, 202903
Practical experiences from Klinik für Gynäkologie, Die Charité – Universitätsmedizin Berlin, Germany
ESGO eAcademy, Jacek Grabowski, 202739
ROBOTIC EXPERT VIDEO
ESGO eAcademy, Rainer Kimmig, 261658
CONCLUSION
ESGO eAcademy, Andreas Du Bois, 202736
Q&A and Discussion
ESGO eAcademy, Faculty / Presenter(s), 203120
SELECTING PATIENTS FOR PARP INHIBITION
ESGO eAcademy, Mansoor Mirza, 202735
RELAPSED OVARIAN CANCER: WHAT DOES MAINTENANCE THERAPY OFFER?
ESGO eAcademy, Nicoletta Colombo, 202733
Welcome and introduction
ESGO eAcademy, Christian Marth, 202732
QUESTIONS REMAINED TO BE ANSWERED
ESGO eAcademy, David Cibula, 202728
CIRCULATING TUMOR CELLS: CHALLENGES & PERSPECTIVES IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Catherine Alix-Panabieres, 202731
SLN IMPLEMENTATION INTO MANAGEMENT ALGORITHMS
ESGO eAcademy, Nadeem Abu Rustum, 202727
DETECTION OF METHYLATED DNA IN VARIOUS BODY FLUIDS AND THEIR USE AS DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TOOLS IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Heidi Fiegl, 202730
DEVELOPMENTS IN DETECTION TECHNIQUES
ESGO eAcademy, Eric Leblanc, 202726
WHOLE-GENOME SEQUENCING OF CELL-FREE DNA IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Adriaan Vanderstichele, 202729
Ultrasound Characteristics Of Endometrial Cancer As Defined By The International Endometrial Tumor Analysis (IETA) Consensus Nomenclature- A Prospective Multicenter Study
ESGO eAcademy, Daniela Fischerova, 202910
LION – LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL.
ESGO eAcademy, Domenica Lorusso, 202722
UTERINE CORPUS
ESGO eAcademy, Sigurd Lax, 202725
WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?
ESGO eAcademy, Isabel Carriles, 202721
OVARY AND FALLOPIAN TUBE
ESGO eAcademy, Matias-Guiu Guia, 202724
PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL
ESGO eAcademy, Sarah Kitson, 202719
CERVIX, VULVA, VAGINA
ESGO eAcademy, Glenn McCluggage, 202723
Development And Pre-Testing Of The Eortc Quality Of Life Questionnaire For Vulva Cancer Patients – The Significance Of Patient Involvement
ESGO eAcademy, Pernille Jensen, 202909
Closing and remarks
ESGO eAcademy, Andreas Du Bois, 202716
Being Practical Case 3
ESGO eAcademy, Christian Marth, 202715
Being Practical Case 2
ESGO eAcademy, Nicoletta Colombo, 202714
Being Practical Case 1
ESGO eAcademy, Isabelle Ray-Coquard, 202713
SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
ESGO eAcademy, Felix Hilpert, 202712
Introduction
ESGO eAcademy, Andreas Du Bois, 202711
Prognostic Factors For Local Recurrence Of Squamous Cell Carcinoma Of The Vulva: A Systematic Review
ESGO eAcademy, Nienke Te Grootenhuis, 202908
The New Normal; Sexual Function after Ovarian Cancer for Survivors and Partners Compared to Normdata
ESGO eAcademy, Maria Caroline Vos, 202907
HOW LONG SHOULD HORMONAL TREATMENT BE CONTINUED BEFORE DECIDING FOR HYSTERECTOMY IN THE FERTILITY SPARING MANAGEMENT OF ENDOMETRIAL CANCER?
ESGO eAcademy, Nicoletta Colombo, 202704
VULVA CANCER
ESGO eAcademy, Ate van der Zee, 202709
The Role Of The Peritoneal Cancer Index In Surgery For Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202906
FERTILITY SPARING MANAGEMENT IN CERVICAL CANCERS BETWEEN 2 AND 4 CM: RADICAL TRACHELECTOMY BY LAPAROTOMY OR NEO-ADJUVANT CHEMOTHERAPY?
ESGO eAcademy, Ignace Vergote, 202703
OVARIAN CANCER
ESGO eAcademy, Christoph Grimm, 202708
The Peritoneal Cancer Index(PCI): Selted Regions - And Not The Total PCI - Are Predictive Of Survival In Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202905
CAN WE SAFELY USE OVARIAN HYPERSTIMULATION IN INFERTILE PATIENTS AFTER FSS FOR EPITHELIAL TUMORS?
ESGO eAcademy, Dominik Denschlag, 202702
CERVICAL CANCER
ESGO eAcademy, Daniela Fischerova, 202707
FERTILITY SPARING MANAGEMENT IN HIGH RISK EPITHELIAL OVARIAN CANCER
ESGO eAcademy, Enrica Bentivegna, 202701
Imaging in the diagnosis and management of endometrial cancer
ESGO eAcademy, Ingfrid Haldorsen, 202706
CHANGES IN NEOANGIOGENETIC PROFILE OF PAIRED PRIMARY AND RECURRENT HIGH-GRADE SEROUS OVARIAN CANCER (HGOSC): A STUDY OF THE “OCTIPS” CONSORTIUM.
ESGO eAcademy, Ilary Ruscito, 202699
CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)
ESGO eAcademy, Umesh Mahantshetty, 202698
AGO-OVAR 12: A RANDOMIZED PLACEBO-CONTROLLED GCIG/ENGOT-INTERGROUP PHASE III TRIAL WITH CHEMOTHERAPY +/- NINTEDANIB FOR ADVANCED OVARIAN CANCER: OVERALL SURVIVAL RESULTS
ESGO eAcademy, Isabelle Ray-Coquard, 202697
EMBRACE THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202696
Randomized Controlled Phase III Study To Evaluate Secondary Cytoreductive Surgery In Platinum-Sensitive Recurrent Ovarian Cancer - AGO Desktop III/ENGOT Ov20
ESGO eAcademy, Jalid Sehouli, 202904
Medical treatment of uterine carcinosarcoma
ESGO eAcademy, Isabelle Ray-Coquard, 190586
Surgical treatment of serous endometrial cancer
ESGO eAcademy, Frederic Guyon, 190585
Long- term therapy with gonadoliberin analogues in patient with ovarian cancer.
ESGO eAcademy, Faculty / Presenter(s), 191006
High grade serous ovarian cancer stage IV, multiple relapses
ESGO eAcademy, Faculty / Presenter(s), 191003
Ovarian Cancer in Pregnancy
ESGO eAcademy, Faculty / Presenter(s), 190595
Surgical treatment of low grade serous ovarian cancer
ESGO eAcademy, Jalid Sehouli, 180471
Medical Tumor Therapy for Germ Cell Tumors of Adults
ESGO eAcademy, Michael Seckl, 180466
Systemic treatment for low grade serous carcinoma
ESGO eAcademy, Michael Seckl, 180469
Surgical treatment for malignant germ cell tumor.
ESGO eAcademy, Pauline Wimberger, 180467
Pathologic aspects of Germ Cell Tumors
ESGO eAcademy, Doris Mayr, 180468
Pathologic aspects of Low Grade Serous Ovarian Cancer
ESGO eAcademy, Doris Mayr, 180470
Look into the future: Medical treatment of ovarian cancer in 2026
ESGO eAcademy, Ignace Vergote, 173572
Immunotherapy in gynecological malignancies
ESGO eAcademy, An Coosemans, 173570
Why do studies of targeted treatment fail?
ESGO eAcademy, Jonathan Ledermann, 173568
Targeting PARP: Mechanisms of action, available evidence, selection of patients, management of toxicities
ESGO eAcademy, Jonathan Ledermann, 173567
Targeting tyrosine kinases
ESGO eAcademy, Jonathan Ledermann, 173566
Molecular pathways in cervical cancer
ESGO eAcademy, Heidi Lyng, 173565
Molecular pathways in endometrial cancer
ESGO eAcademy, Henrica Maria Johanna Werner, 173564
Molecular pathways of low-grade ovarian cancer
ESGO eAcademy, Kristina Lindemann, 173563
Molecular pathways of high grade ovarian cancer
ESGO eAcademy, Adriaan Vanderstichele, 173562
Surgical aspects of uterine carcinosarcoma (~ serous)
ESGO eAcademy, Frederic Amant, 173558
Ultrasound guided procedures
ESGO eAcademy, Michal Zikan, 173920
Ovarian cancer staging
ESGO eAcademy, Daniela Fischerova, 173919
Endometrial cancer diagnosis and staging
ESGO eAcademy, Elisabeth Epstein, 173918
Cervical cancer staging
ESGO eAcademy, Antonia Testa, 173917
Abdominal scan
ESGO eAcademy, Daniela Fischerova, 173916
Pelvic imaging
ESGO eAcademy, Daniela Fischerova, 173915
Introduction
ESGO eAcademy, David Cibula, 173914
Uterine carcinosarcoma: radiotherapy
ESGO eAcademy, Carien Creutzberg, 173556

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings